Pluri, Inc.
New York
New York
United States
357 articles about Pluri, Inc.
-
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
3/14/2024
Pluri Inc. announced that its CDMO division has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
-
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
3/11/2024
In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. announced an important expansion to its intellectual property portfolio with a new patent approval, that is designed to reshape the agricultural technology landscape.
-
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
3/6/2024
Pluri Inc. announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board.
-
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
2/28/2024
Leading biotechnology company Pluri Inc. issued the following update from CEO and President, Yaky Yanay.
-
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
1/8/2024
Pluri Inc. announced it has launched a new business division offering cell therapy manufacturing services as a Contract Development and Manufacturing Organization : PluriCDMO™.
-
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
12/21/2023
Pluri Inc. announced it has signed an agreement assigning the joint patent rights to develop Pluri’s PLX cells in the treatment of cocaine addiction, to BIRAD–Research & Development Company Ltd., the commercial arm of Bar-Ilan University.
-
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
7/13/2023
Pluri Inc., a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, announced the appointment of Lorne Abony to the Company’s Board of Directors, effective as of July 11, 2023.
-
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome
7/11/2023
Pluri Inc. announced that it has signed a three year $4.2M contract with the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
-
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
4/27/2023
Pluri Inc., a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, unveiled a breakthrough in cell manufacturing that potentially solves one of the biggest hurdles facing cell-based industries: cost-effective, industrial scale cell manufacturing.
-
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept
12/22/2022
Pluri Inc., a leading biotechnology Company, issued the following update to shareholders from CEO and President Yaky Yanay and announced that as planned the Company’s joint venture with Tnuva Group has successfully achieved proof of concept in its development of cultivated meat based on Pluri’s proprietary 3D cell-based technology platform.
-
Pluri wins BioTech Breakthrough Cell Innovation of the Year Award
11/10/2022
Pluri Inc., a leading biotechnology company, won Cell Innovation award in the Cell Biology category of the second annual BioTech Breakthrough Awards.
-
Pluri to Present and Participate in Upcoming Conferences
10/31/2022
Pluri Inc. today announced its participation in three upcoming conferences. Conference: CPHI Frankfurt Date: November 1-3, 2022 Location: Frankfurt, Germany.
-
Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
9/29/2022
Pluri Inc. today issued the following update to shareholders from Chief Executive Officer and President Yaky Yanay announcing that it had signed its second technology collaboration agreement centered on Pluri’s 3D cell expansion platform and providing some financial status updates.
-
MacroGenics' Phase II trial shuts down after a patient death believed to be related to enoblituzumab combo, while Exelixis' Cabometyx combo improves PFS in renal cell carcinoma.
-
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
7/13/2022
Pluristem Therapeutics Inc., a leading biotechnology company, announced topline results from its multinational double-blind, placebo-controlled phase III study.
-
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
3/23/2022
Pluristem Therapeutics Inc. today announced positive final results from its innovative hematology Phase I study to evaluate the safety and exploratory efficacy of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following HCT
-
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
3/8/2022
Pluristem Therapeutics Inc. and Tnuva Group jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat.
-
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
2/24/2022
Leading biotechnology company Pluristem Therapeutics Inc. and Israel’s largest food producer Tnuva Group announced the closing of its landmark collaboration to develop, manufacture and commercialize cell-based products for the food industry.
-
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
1/10/2022
Pluristem Therapeutics Inc., a leading biotechnology company, and Tnuva Group, Israel’s largest food producer, announced the launch of an innovative collaboration to develop, manufacture and commercialize cultured cell-based products for the food industry.
-
Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19
12/27/2021
Pluristem Therapeutics Inc. today announced topline results from its Phase II dose escalation studies evaluating the safety and efficacy of intramuscular injections of PLX-PAD cells for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.